5-氟尿嘧啶磁性载药微球靶向治疗裸鼠人胰腺癌
被引量:2
摘要
肿瘤靶向治疗是指利用具有一定特异性的载体,将能杀伤肿瘤细胞的药物和基因等选择性地运送到肿瘤部位,把治疗作用或药物效应尽量限定在特定的靶细胞、组织或器官内,而不影响正常细胞、组织或器官的功能,从而提高疗效、减少毒副作用的一种方法。我们以5-氟尿嘧啶(5-Fu)作为模型药,乳化热固化法制备5-Fu磁性载药微球(5-Fu-MAMS),体外循环装置考察其磁定位规律并观察对裸鼠人胰腺癌PC-3移植瘤的疗效。
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2008年第2期262-262,共1页
Chinese Journal of Experimental Surgery
基金
贵州省优秀科技教育人才省长专项基金资助项目[黔科教办(2001)3号]
参考文献4
-
1Brlgger I, Dubemet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev ,2002,54:631-651.
-
2Hioki Y, Masaji T, Hironobu O, et al. Locoregional chemotherapy for patients with pancreatic cancer intr-arterial adjuvant chemotherapy after pancreatectomy with portal vein reseaction. Pancreas,2002,25:366-372.
-
3Hawes RH, Xiong Q, Waxman I, et al. A multispeciality approach to the diagnosis and management of pancreatic cancer. Am J GastroenteroI,2000:95:17.
-
4陶凯雄,孙宏武,陈道达,吴在德,田源,杨秀萍.阿霉素磁性蛋白微球靶向治疗鼠种植性胃肿瘤[J].中华实验外科杂志,2000,17(1):63-64. 被引量:11
二级参考文献2
-
1Shimomura K,Manda T,Mukumoto S,et al.Antitumor activity and hematotoxicity of a new, substutited dihydrobenzoxazine,FK973, in mice[].Cancer Research.1988
-
2Marks DC,Belov L,Davey MW,et al.The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells[].Leukemia Research.1992
共引文献10
-
1程新宝,袁曙光,阎东,李玛琳.磁性微粒协同外置磁场的抗肿瘤活性作用:实验性研究[J].放射学实践,2004,19(6):449-450. 被引量:3
-
2蔡明,王国斌,陶凯雄,蔡昌学.纳米技术在肿瘤治疗中的应用[J].中国医师杂志,2007,9(9):1292-1293.
-
3田连芳.抗人大肠癌免疫磁性白蛋白微球的抗癌效果[J].军医进修学院学报,2008,29(1):38-40.
-
4张吉林,洪广言,倪嘉缵.单分散磁性纳米粒子靶向药物载体[J].化学进展,2009,21(5):880-889. 被引量:20
-
5何山红,秦子敏,李印.磷酸果糖激酶4在肺癌组织中的表达及其临床意义[J].中华实验外科杂志,2014,31(8):1632-1634.
-
6孔丽君,王清明,陈惠鹏.肿瘤导向治疗研究进展[J].生物技术通讯,2002,13(6):459-461. 被引量:1
-
7董广星,陈旭.靶向药物阿霉素抗肿瘤研究新进展[J].天津药学,2003,15(2):60-63. 被引量:4
-
8赵慧君,王德平,黄文旵,张娟.磁性纳米微球的特性及其在生物医学中的应用[J].同济大学学报(医学版),2003,24(4):288-291. 被引量:13
-
9罗莎,吴华.肿瘤靶向诊断及治疗中的导向系统研究进展[J].放射学实践,2004,19(1):64-66. 被引量:2
-
10程新宝,袁曙光,阎东.磁性微粒栓塞肝癌临床与病理分析[J].肿瘤学杂志,2004,10(3):162-164.
同被引文献23
-
1潘耀振,孙诚谊,王玉芝.脂质体介导的IGF-1R反义寡核苷酸抗胰腺癌的实验研究[J].中华核医学杂志,2005,25(4):212-215. 被引量:2
-
2Lamber E, Ress jKH,Tweetymun PR, et al. Resistance circamvention strategies tested in clinical leukemia specimens using the MTT colori- metric assay. Leukemia, 1992,6 : 1063-1067.
-
3Stuart DD, Alien TM. A new liposomal formulation for antiserse oli- gocleoxynueleotides with small size, high incorporation efficiency and good stability. Biochem Bio Acta,2000,63:219-229.
-
4Chan JY, Chu AC, Fung KP, et al. Inhibition of P-glyeoprotein expres- sion and reversal of drag resistance of human hepatoma HepG2 cells by multidrug resistance gene (mdrl) antisense RNA. Life Sci. 2000,67:2117-2124.
-
5Agata Y,Matsuda E,Shimizu A. Two novel Kruppel-associated boxcontaining zinc-finger proteins,KRAZ1 and KRAZ2,repress transcription through functional interaction with the corepressor KAP-1(T1Flbeta/KR1P-1)[J].{H}Journal of Biological Chemistry,1999,(23):16412-16422.
-
6Friedman JR,Fredericks WJ,Jensen DE. KAP-1,a novel corepressor for the highly conserved KRAB repression domain[J].{H}Genes and development,1996,(16):2067-2078.
-
7Kim SS,Chen YM,O' Leary E. A novel member of the RING finger family,KRIP-I,associates with the KRAB-A transcriptional repressor domain of zinc finger proteins[J].{H}Proceedings of the National Academy of Sciences(USA),1996,(26):15299-15304.
-
8Wolf D,Goff SP. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells[J].{H}CELL,2007,(1):46-57.
-
9Ellenrieder V,Hendler SF,Ruhland C. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system[J].{H}International Journal of cancer,2001,(2):204-211.
-
10Nakajima S,Doi R,Toyoda E. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma[J].{H}Clinical Cancer Research,2004,(12 Pt 1):4125-4133.
引证文献2
-
1潘耀振,孙诚谊,权广前,喻超.反义寡核苷酸联合磁性载药微球靶向治疗耐药裸鼠人胰腺癌[J].中华实验外科杂志,2012,29(1):23-25. 被引量:1
-
2詹磊,江建新,潘耀振,孙诚谊.KRAB-相关蛋白1对胰腺癌细胞化疗耐药性的影响[J].中华实验外科杂志,2014,31(1):12-15.
-
1李春生,寿崇琦,左志俊.载药微球释放规律的实验研究[J].化学研究与应用,1999,11(3):302-304. 被引量:2
-
2李春生,寿崇琦,左志俊.磁性载药微球的制备[J].化工新型材料,1999,27(7):31-32. 被引量:2
-
3王瑞,何景华.FTY720抑制人胰腺癌Miopac2细胞株增殖的研究[J].天津医科大学学报,2008,14(4):445-447. 被引量:7
-
4杨秀岭,张志清,董立,李素民,樊德厚.阿昔洛韦白蛋白微球的制备及体外释药[J].中国药学杂志,2000,35(10):676-678. 被引量:10
-
5殷佩浩,李琦,李先茜,秦爱军,范跃祖.蟾毒灵对裸鼠人胰腺癌的作用和诱导细胞调亡的研究[J].中国实用医药,2007,2(9):19-22. 被引量:4
-
6孟凡虹,包群,陆信.人胰腺癌体外抗肿瘤药物敏感性分析研究[J].昆明医学院学报,1993,14(1):8-10.
-
7孙诚谊,喻超,刘建刚,王王芝.磁性氟尿嘧啶白蛋白微球抗人胰腺癌的实验研究[J].中华肝胆外科杂志,2008,14(10):739-741. 被引量:2
-
8刘志超,刘建刚,孔霞,姜涛,顾洁.氟尿嘧啶磁性白蛋白微球在人结直肠癌裸鼠体内的生物分布研究[J].中华胃肠外科杂志,2012,15(6):622-624. 被引量:3
-
9文小平,李琦,李先茜,殷佩浩,王炎,秦爱军.蟾毒灵诱导人胰腺癌细胞凋亡及其对TGF-β1表达的影响[J].中国实用医药,2007,2(18):1-4. 被引量:3
-
10鲍家科,王薇.盐酸乙胺丁醇微球的制备及体外释药性能[J].中国医院药学杂志,2000,20(11):655-656. 被引量:1